Author: bdinews

Funding and opportunities – 22 September 2020

CSL Collaboration and Partnering Opportunities – Call for Submissions

Submission deadline: Saturday 10 October 2020

CSL is seeking academic collaborators and partnering opportunities in the following areas:

• B cell and plasma depletion
  CSL is interested in research in the broader area of autoimmunity, with a focus on autoantibody, complement and T cell‑mediated diseases.
• Progressive Fibrosing Interstitial Lung Diseases and Acute Respiratory Distress Syndrome
  CSL is interested in respiratory therapeutics in the areas of Interstitial Lung Diseases (ILD) and Acute Respiratory Distress Syndrome (ARDS).
• Cardiovascular disorders
  CSL is interested in research developing novel therapeutic candidates or exploring novel drug targets for cardiovascular disease, with a particular focus on rare cardiovascular diseases.

Submission Information
Non‑confidential one‑page research summaries are encouraged, plus any relevant non‑confidential supporting documents.

Submission Deadline: Please submit a one-pager to Celine Latouche (celine.latouche@monash.edu) by 10 October 2020 for compliance check by the Business Development Team and Monash Innovation. Also feel free to discuss your project and seek support to draft this one-pager at any time before the internal deadline.

Funding and opportunities – 22 September 2020

New Funding Opportunity: Johnson & Johnson WiSTEM2D

Completed EOI form (and attached resume) due to MRO: Wednesday 30 September 2020
Approximate expected outcome of the EOI: Thursday 8 October 2020
(09:00 Honolulu Standard Time) Applications close: Thursday 15 October 2020

The Johnson & Johnson Scholars Program aims to fuel the development of female STEM2D leaders and feed the STEM2D talent pipeline by awarding and sponsoring women at critical points in their research careers, in each of the STEM2D disciplines:

• Science
• Technology
• Engineering
• Math
• Manufacturing
• Design

The awards will fund one woman per discipline (worldwide) who has completed her advanced degree, who is working as a Senior Lecturer or Lecturer (or other appointment that could be equivalent to “Assistant Professor” in the USA) and who is not yet tenured at an accredited university or design institution. Adjunct staff are not eligible. The Award is for $150,000 USD over three years.

For more details about the opportunity, please see the call page and FAQs.

Internal Monash EOI

Monash may only submit one application per each of the six categories. Therefore, the MRO is calling for expressions of interest (EOIs) in advance, to determine the lead applicant in each category. Interested researchers should complete the attached form and return it by email to mhs@monash.edu (with attached resume) on or before Wednesday 30 September 2020. No letters are required for the EOI. An application in Pure is also not required for the EOI.

After the EOI concludes, successful shortlisted applicants will be invited to apply to Johnson & Johnson. A letter of recommendation from the relevant Head of Department/School will be required at that stage.

If you have any questions, please contact mhs@monash.edu.

Funding and opportunities – 22 September 2020

Monash University – Baker Institute Seed Funding for Collaborations in Cardiovascular Research

EOI submission due: Monday 28 September 2020

Monash University’s Faculty of Medicine, Nursing and Health Sciences (MNHS) and the Baker Institute are jointly funding a seed grant scheme, to further enhance collaborative cardiovascular research. Researchers are invited to submit an Expression of Interest (EOI) for funding up to $100,000 for collaborative projects.

Projects that aim to bring together basic research and clinical expertise will be favoured. New collaborations between Monash and the Baker Institute are encouraged but existing collaborations will also be considered.

The opportunity is open to all Baker Institute and MNHS staff (with at least a 0.4 FTE appointment) and applications must include at least one investigator from each institution.

EOI submissions are due on 28 September 2020, with selected applicants invited to submit a full proposal by 13 November 2020. Successful applicants will be announced in December for projects to commence in January 2021.

To submit an EOI, please complete the form available here.

Questions should be directed to the MNHS Faculty Research Office (medicine.research@monash.edu) in the first instance.

Funding and opportunities – 22 September 2020

A Call for Collaborative Medicinal Chemistry Projects 2020-2021

Expressions of interest (EOI) due: Saturday 31 October 2020

The Australian Translational Medicinal Chemistry Facility (ATMCF) provides Australian researchers with an opportunity to:

• access subsidised medicinal chemistry
• access the Therapeutic Innovation Australia (TIA) Pipeline Accelerator for further cost reductions
• work with a team of medicinal chemists who have a proven track record in drug discovery and commercialisation outcomes

The ATMCF is a national drug discovery capability that applies medicinal chemistry expertise to translate biomedical research towards clinical relevance. Facilitated by Therapeutic Innovation Australia (TIA), and based at The Monash Institute of Pharmaceutical Sciences (MIPS), Parkville, the ATMCF collaborates with researchers to identify and synthesize bioactive compounds (small molecules) which are optimized through medicinal chemistry against a range of potency, selectivity and pharmacokinetic criteria.

Do you require assistance in finding the right biologically active compound for your target or disease of interest? Not sure that you have adequate funding for a medicinal chemistry project? Talk to the ATMCF. They will work with you, and our partners, to discuss shared risk options and/or other funding opportunities for cost leveraging on your project.

Expressions of Interest (EOI) due on 31 October 2020. A short EOI template is available upon request.

Contact: leanne.hawkey@monash.edu

 

Funding and opportunities – 15 September 2020

ARC – Australian Laureate Fellowships (FL21) Now Open

RNTA due to MRO: Wednesday 14 October 2020
ADR Approved Strategic Statements Due to MRO: Wednesday 21 October 2020
ARC Deadline: Wednesday 4 November 2020
Anticipated Rejoinder Period: 10 February – 23 February 2021

Funder: Australian Research Council (ARC)

Funding Opportunity: ARC Australian Laureate Fellowship

The Australian Laureate Fellowships (including Kathleen Fitzpatrick and Georgina Sweet Australian Laureate Fellowship) scheme encourages applications from the highest-quality researchers by providing eligible Australian Laureate Fellows with project funding in addition to a salary supplement and salary-related (on-cost) support.

Important Notes

• To assist researchers in planning applications for upcoming ARC grant opportunities, the ARC has published pre-award guidance on the ARC website, including Frequently Asked Questions (FAQs) that relate to the impacts of COVID-19.
• Following the updated ARC Conflict of Interest and Confidential Policy, there are some new mandatory questions which must be completed via the Personal Details tab of each RMS user profile.
• Key change to FL21 ITA: D1- Project description includes an additional sub-section “Project Aims and Background”.

If you are considering to apply for these schemes and have not yet contacted the MRO’s Research Development team, please do so as soon as possible via mro.researchdevelopment@monash.edu.

Please find attached:

• Discovery Program and Grant Guidelines
• FL21 Instructions to Applicants
• RNTA form
• FL21 – D1 – Project Description template
• FL21 F6 Template
• FL21 – F15 – ROPE Template
• Certification form

All these are are also available via the MRO intranet, including our Guide to entering Research Outputs into RMS.

Further information about the FL, including sample application forms, can be found at Grant Connect (GO4347).

Please contact us at mro-applications@monash.edu if you have any queries about this funding opportunity.